Page 1: Executive summary

Market Overview

Page 2: Global Oncology Pharmaceuticals Market - Overview, Size & Growth (Value: 2007 and 2013e),

Page 3: Indian Oncology Pharmaceuticals Market- Overview, Size & Growth (Value: 2010-2016e)

Page 4: Overview of cancer prevalence in India

Page 5-6: EXIM statistics of oncology pharmaceuticals (Value: 2006-07 to 2010-11)

Drivers & Challenges

Page 7: Summary

Page 8-12: Drivers

Page 13-15: Challenges

Government Initiatives

Page 16: Summary

Page 12- 21: Government Initiatives

Market value chain, regulation and patents

Page 22: Pharmaceutical value chain

Page 23: Phases of clinical trials

Page 24: Indian government functions in licensing and registration of pharmaceuticals

Page 25: Indian drug regulatory frameworks

Page 26- 27: List of patent approvals by US FDA

Page 28: List of oncology drug marketing approvals in India

Competition

Page 29: Market Competition - Porter's Five Forces Analysis

Page 30- 63: Major public players

Page 58- 69: Major private players

Page 70: Recent Developments

Strategic Recommendation

Page 71: Strategic Recommendations

Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, the Indian market is characterized by a huge demand for cancer drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of cancer cases, specially in lung cancer and breast cancer cases; changes in the cancer treatment scenario, development of alternative cancer therapies, increased cancer health insurance coverage and increasing amount of foreign direct investment (FDI) is helping the market to grow. The Indian Government, on its part is taking initiatives to work out public-private partnership projects (PPP) and reduce the essential drug prices. The market is expected to exhibit steady growth over the next few years.

The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included.

An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems.

The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals.

The competition section gives overview of pharmaceutical companies in the country operating in the oncology pharmaceutical industry. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Oncology Pharmaceutical industry.

The section on strategic recommendations elaborates on decisions that existing players as well as new entrants can find it useful. The foray into generic drugs is oncology segment can be beneficial for the players to a large extent.